MX367782B - Moduladores de la sintesis de andrógenos. - Google Patents

Moduladores de la sintesis de andrógenos.

Info

Publication number
MX367782B
MX367782B MX2015003899A MX2015003899A MX367782B MX 367782 B MX367782 B MX 367782B MX 2015003899 A MX2015003899 A MX 2015003899A MX 2015003899 A MX2015003899 A MX 2015003899A MX 367782 B MX367782 B MX 367782B
Authority
MX
Mexico
Prior art keywords
modulators
androgen synthesis
androgen production
compositions
androgen
Prior art date
Application number
MX2015003899A
Other languages
English (en)
Other versions
MX2015003899A (es
Inventor
Jane Dilly Suzanne
Alan Stoloff Gregory
Christopher Taylor Paul
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of MX2015003899A publication Critical patent/MX2015003899A/es
Publication of MX367782B publication Critical patent/MX367782B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente especificación describe composiciones que comprenden al menos un compuesto terapéutico capaz de modular la producción de andrógenos y los métodos y usos para el tratamiento de un trastorno asociado con la producción de andrógenos, usando tales composiciones y/o compuestos.
MX2015003899A 2012-09-26 2013-09-26 Moduladores de la sintesis de andrógenos. MX367782B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705790P 2012-09-26 2012-09-26
US201361871662P 2013-08-29 2013-08-29
PCT/EP2013/070106 WO2014049071A1 (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis

Publications (2)

Publication Number Publication Date
MX2015003899A MX2015003899A (es) 2015-11-25
MX367782B true MX367782B (es) 2019-09-04

Family

ID=49293617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003899A MX367782B (es) 2012-09-26 2013-09-26 Moduladores de la sintesis de andrógenos.

Country Status (14)

Country Link
US (4) US9072743B2 (es)
EP (1) EP2900270B1 (es)
JP (2) JP6434410B2 (es)
CN (1) CN104797271B (es)
AU (2) AU2013322612B2 (es)
BR (1) BR112015006727B1 (es)
CA (1) CA2886132C (es)
ES (1) ES2734554T3 (es)
HK (1) HK1211868A1 (es)
IL (2) IL237892B (es)
MX (1) MX367782B (es)
NZ (1) NZ706067A (es)
PL (1) PL2900270T3 (es)
WO (1) WO2014049071A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) * 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis
WO2018136758A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hsd17b13 variants and uses thereof
MX2019012169A (es) * 2017-04-11 2019-12-11 Regeneron Pharma Ensayos para evaluar la actividad de moduladores de miembros de la familia de hidroxiesteroide (17-beta) deshidrogenasa (hsd17b).
JP7434151B2 (ja) 2017-10-11 2024-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｎｐｌａ３ ｉ１４８ｍの変異を発現している患者の肝疾患の治療におけるｈｓｄ１７ｂ１３の阻害
AU2019239971B2 (en) 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPH05502217A (ja) * 1989-08-21 1993-04-22 ベス　イスラエル　ホスピタル　アソシエーション セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6319950B1 (en) 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
JPH1192343A (ja) * 1997-09-22 1999-04-06 Shiseido Co Ltd 毛髪成長期延長剤
JPH11209279A (ja) * 1998-01-05 1999-08-03 Natural Ltd As 体重減少および肥満処置の方法
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
CA2475839A1 (en) * 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1626703A2 (en) * 2003-05-22 2006-02-22 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2005066196A1 (en) * 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
AU2006252708A1 (en) * 2005-05-31 2006-12-07 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
WO2008034129A2 (en) * 2006-09-15 2008-03-20 Cornell Research Foundation Inc. Treatment of cancer or obesity with conjugated linoleic acids
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
AR070313A1 (es) * 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
CN102083787A (zh) * 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
CN101366705B (zh) * 2008-09-28 2010-09-08 浙江大学 利培酮透皮吸收贴片
US20110008436A1 (en) 2009-04-20 2011-01-13 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
WO2012026663A1 (ko) * 2010-08-25 2012-03-01 이화여자대학교 산학협력단 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
JP2014510045A (ja) * 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
WO2014027973A1 (en) * 2012-08-14 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Paliperidone oral solution
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
AU2015257594A1 (en) 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
AU2013322612A2 (en) 2015-04-09
WO2014049071A1 (en) 2014-04-03
HK1211868A1 (en) 2016-06-03
CN104797271B (zh) 2020-03-06
US9072743B2 (en) 2015-07-07
EP2900270B1 (en) 2019-03-06
AU2017221819A1 (en) 2017-09-21
JP2015532920A (ja) 2015-11-16
BR112015006727B1 (pt) 2022-08-16
US20180064713A1 (en) 2018-03-08
US20170189407A1 (en) 2017-07-06
US20150258095A1 (en) 2015-09-17
JP6434410B2 (ja) 2018-12-05
IL266446A (en) 2019-06-30
US9585887B2 (en) 2017-03-07
AU2017221819B2 (en) 2019-05-02
IL237892A0 (en) 2015-05-31
MX2015003899A (es) 2015-11-25
CN104797271A (zh) 2015-07-22
PL2900270T3 (pl) 2019-09-30
US9808462B2 (en) 2017-11-07
US20140088120A1 (en) 2014-03-27
ES2734554T3 (es) 2019-12-10
AU2013322612A1 (en) 2015-04-09
EP2900270A1 (en) 2015-08-05
JP2019052159A (ja) 2019-04-04
BR112015006727A8 (pt) 2019-08-27
CA2886132C (en) 2023-03-21
IL237892B (en) 2019-05-30
CA2886132A1 (en) 2014-04-03
BR112015006727A2 (pt) 2017-07-04
JP6734346B2 (ja) 2020-08-05
NZ706067A (en) 2016-07-29
AU2013322612B2 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
PH12015500180A1 (en) Compounds that are s1p modulating agents and/or atx modulating agents
IN2015DN00438A (es)
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MY177031A (en) Tetrahydropyridopyrazines modulators of gpr6
IN2015DN00598A (es)
MX2015003899A (es) Modulares de la sintesis de andrógenos.
PH12014502032A1 (en) Treatment of brain cancer
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
GB2498325A (en) Modulation neural pathways
IN2014DN07636A (es)
IL263781A (en) Combined treatment of ovarian cancer
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
CA2875305C (en) Fbxo3 inhibitors
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.
IN2014DN07989A (es)
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
UA76841U (en) Feed additive "echinobioactive"
UA75455U (ru) Способ профилактики протезного стоматита
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA76756U (ru) Способ лечения псориаза
IN2013MU02509A (es)

Legal Events

Date Code Title Description
FG Grant or registration